Moody Aldrich Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Moody Aldrich Partners’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-22,372	Closed	-$1.02M	–	117
2018 Q2	$1.02M	Sell	22,372 -4,405	-16%	-$214K	0.36%	85
2018 Q1	$1.41M	Buy	26,777 +5,871	+28%	+$343K	0.91%	61
2017 Q4	$1.42M	Buy	20,906 +4,006	+24%	+$280K	1.15%	39
2017 Q3	$1.39M	Buy	16,900 +3,210	+23%	+$254K	1.43%	24
2017 Q2	$1.28M	Buy	13,690 +2,885	+27%	+$177K	1.6%	15
2017 Q1	$688K	Buy	+10,805	New	+$657K	1.18%	34
2016 Q4	–	Sell	-20,730	Closed	-$747K	–	104
2016 Q3	$747K	Buy	+20,730	New	+$445K	0.52%	83

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Moody Aldrich Partners's CLVS Position: Q3 2018 in Review

Moody Aldrich Partners sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 22,372 shares — an estimated $1.02M sold.

Moody Aldrich Partners first reported a position in CLVS in Q3 2016 and held it in 7 quarters. The position peaked at $1.42M in Q4 2017. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

Moody Aldrich Partners reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
Moody Aldrich Partners sold 22,372 Clovis Oncology, Inc. shares in Q3 2018, an estimated $1.02M.
Moody Aldrich Partners first reported a position in Clovis Oncology, Inc. in Q3 2016 and held it in 7 quarters.
Moody Aldrich Partners's Clovis Oncology, Inc. position peaked at $1.42M in Q4 2017.
192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Moody Aldrich Partners's 13F filing for Q3 2018, filed 31 Oct 2018.